SEOUL-SEMICONDUCTOR
20.10.2020 04:32:07 CEST | Business Wire | Press release
Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED products and technology, announced that LED Luks , a European manufacturer of LED luminaires, has adopted Seoul Semiconductor’s SunLike Series natural spectrum LEDs for private kindergarten facilities’ lighting in Slovenia to support children’s learning and eye health.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201019005912/en/
In cooperation with LED Luks, Seoul Semiconductor has developed the optimal SunLike Series LED designs based on the natural spectrum light source for the lighting. With SunLike Series natural spectrum LED technology, LED Luks has used lighting brand “ARUN” to support children’s concentration and relaxation with an optimal smart solution for remotely and automatically adjusting the color temperature and dimming representing the light from noon to evening.
The light in noon color mode helps children’s brains more alert and also improve academic performance. The light in the evening color mode makes them more creative and feel relaxed. It also provides high sleep quality by promoting melatonin, thus encouraging the production of growth hormone and boosting memory and immunity. Human body produces growth hormone up to 80% of the daily GH production during sleep. Deep, non-REM sleep helps human brain to wash away waste and to regenerate cells, supporting immunity.
Earth is estimated to be 4.5 billion years old. With natural sunlight, under which all animals on the earth have evolved over 3.9 billion years, plants over 450 million years, insects over 360 million years, and humans over 7 million years. Based on circle of day – month – year, human’s DNA has evolved and a circadian rhythm is internal process that regulates the sleep-wake cycle based on 24-hour body clock that natural sunlight affects.
SunLike Series LEDs are the world’s first technology and have been recognized as an innovative technology that produces light that closely matches the spectrum of natural sunlight by a total of ten global lighting awards held in Korea, Europe, China, and the US over the past three years. Based on the results of a comprehensive sleep study conducted by Professor Christian Cajochen and his colleagues at the University of Basel in Switzerland, LED light sources with the same measured intensity and correlated color temperature (CCT), but different spectral output, can have different effects on human behavior and physiology. The study, published in the Journal of Lighting & Research Technology on March 24, 2019, found “evidence that daylight [natural spectrum] LED solution has beneficial effects on visual comfort, daytime alertness, mood, and sleep intensity in healthy volunteers.” According to the results of a study done by the Bio-Information Laboratory of Seoul National University Hospital in July of 2018, SunLike Series natural spectrum LEDs have been shown to reduce eye discomfort and improve sleep patterns. In addition, Seoul Semiconductor has been conducting experiments on protection from myopia and students’ learning and concentration with influential university research teams in Europe and the US for three years, and is expected to announce the study results in the second half of 2020.
“Young people who spend long hours of indoor study and the lack of exposure to daylight particularly need to use a better quality of LED lighting which closely matches natural spectrum of sunlight,” said Carlo Romiti, Europe sales Vice President of Seoul Semiconductor. “We believe that Seoul Semiconductor’s SunLike Series natural spectrum LEDs will be necessary technology for human-centric lighting to support human health, well-being and better performance of daily life, children’s healthy growth as well with three beneficial effects in contrast to conventional LEDs: Better Study, Better Eye Health and Better Immunity.”
Introduced in June 2017, the SunLike Series natural spectrum LEDs are an advanced light source that combine the latest optical and compound semiconductor technology of Seoul Semiconductor with Toshiba Materials’ TRI-R® technology. TRI-R, supported by Toshiba Materials, finds in the definition “The light closest to the sun for human well-being” its original concept. The sunlight spectrum is developed by the same company and can be reproduced by a white LED light source technology. TRI-R is a registered trademark by the Toshiba Materials Co., LTD.
About Seoul Semiconductor
Seoul Semiconductor is the world’s second-largest global LED manufacturer, a ranking excluding the captive market, and has more than 10,000 patents. Based on a differentiated product portfolio, Seoul offers a wide range of technologies, and mass produces innovative LED products for indoor and outdoor lighting, automotive, IT products, such as mobile phone, computer displays, and other applications, as well as the UV area. The company’s world’s first development and mass production products are becoming the LED industry standard and leading the global market with a package-free LED, WICOP; a high-voltage AC-driven LED, Acrich; an LED with 10X the output of a conventional LED, nPola; a cutting edge ultraviolet clean technology LED, Violeds; an all direction light emitting technology, filament LED; a natural spectrum LED, SunLike; and more. For more information, please visit www.seoulsemicon.com/en .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201019005912/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Plasma One Launches to Herald a New Era of Stablecoin Banking19.6.2026 14:29:00 CEST | Press release
Plasma has today announced the launch of Plasma One, its flagship financial product designed to make digital dollars usable for everyday spending, sending and earning. Plasma One is designed to make stablecoins feel like money, only better - more accessible, reliable and efficient. For years, stablecoin adoption has been held back by a fragmented system and poor user experience. We have seen wallets in one place, exchanges in another, and costly off-ramps standing between digital dollars and daily life. Plasma One brings that experience together in a single app, giving users a simple way to spend, send and earn with stablecoins from one account with zero fees. Headquartered in London, the city that gave rise to Revolut, Wise and Monzo, Plasma is making a bigger bet, that the next generation of consumer banking will be built on stablecoin rails, not legacy banking infrastructure. Underneath Plasma One is the Plasma Network, Plasma’s own blockchain, purpose-built to move stablecoins inst
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release
Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d
Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release
New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
